Emmanuel Griessinger

Emmanuel Griessinger

Auto-generated profile, based on publicly available information

Emmanuel Griessinger

Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2010 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
LPLionel Poulin
Lionel Poulin
MSMariolina Salio
Mariolina Salio
EGEmmanuel Griessinger
Emmanuel Griessinger
FAFernando Anjos-Afonso
Fernando Anjos-Afonso
LCLigia Craciun
Ligia Craciun
CSCaetano Reis e Sousa
Caetano Reis e Sousa
In mouse, a subset of dendritic cells (DCs) known as CD8α+ DCs has emerged as an important player in the regulation of T cell responses and a promising target in vaccination strategies. However, translation into clinical protocols has been hampered by the failure to identify CD8α+ DCs in humans. Here, we characterize a population of human DCs that expresses DNGR-1 (CLEC9A) and high levels of BDCA3 and resembles mouse CD8α+ DCs in phenotype and function. We describe the presence of such cells in the spleens of humans and humanized mice and report on a protocol to generate them in vitro. Like mouse CD8α+ DCs, human DNGR-1+ BDCA3hi DCs express Necl2, CD207, BATF3, IRF8, and TLR3, but not CD11b, IRF4, TLR7, or (unlike CD8α+ DCs) TLR9. DNGR-1+ BDCA3hi DCs respond to poly I:C and agonists of TLR8, but not of TLR7, and produce interleukin (IL)-12 when given innate and T cell–derived signals. Notably, DNGR-1+ BDCA3+ DCs from in vitro cultures efficiently internalize material from dead cells and can cross-present exogenous antigens to CD8+ T cells upon treatment with poly I:C. The characterization of human DNGR-1+ BDCA3hi DCs and the ability to grow them in vitro opens the door for exploiting this subset in immunotherapy.

14 July 2016 in Blood
Verified
Journal Article
Open access
PDF file
RMRuxanda Moschoi
Ruxanda Moschoi
VIVeronique Imbert
Veronique Imbert
MNMarielle Nebout
Marielle Nebout
JCJohanna Chiche
Johanna Chiche
DMDidier Mary
Didier Mary
EGEmmanuel Griessinger
Emmanuel Griessinger
Key Points: Bone marrow mesenchymal stromal cells transfer functional mitochondria to AML cells in vitro and in vivo through endocytic pathways. This mitochondria transfer is enhanced by some chemotherapies and confers a survival advantage to leukemic blasts and leukemia initiating cells.

11 March 2010 in Blood
Verified
Journal Article
Closed access
PDF file
DTDavid C. Taussig
David C. Taussig
JVJacques Vargaftig
Jacques Vargaftig
FMFarideh Miraki-Moud
Farideh Miraki-Moud
EGEmmanuel Griessinger
Emmanuel Griessinger
KSKirsty Sharrock
Kirsty Sharrock
DBDominique Bonnet
Dominique Bonnet
Leukemia-initiating cells (LICs) in acute myeloid leukemia (AML) are believed to be restricted to the CD34+ fraction. However, one of the most frequently mutated genes in AML is nucleophosmin (NPM), and this is associated with low CD34 expression. We, therefore, investigated whether NPM-mutated AMLs have LICs restricted to the CD34+ fraction. We transplanted sorted fractions of primary NPM-mutated AML into immunodeficient mice to establish which fractions initiate leukemia. Approximately one-half of cases had LICs exclusively within the CD34− fraction, whereas the CD34+ fraction contained normal multilineage hematopoietic repopulating cells. Most of the remaining cases had LICs in both CD34+ and CD34− fractions. When samples were sorted based on CD34 and CD38 expression, multiple fractions initiated leukemia in primary and secondary recipients. The data indicate that the phenotype of LICs is more heterogeneous than previously realized and can vary even within a single sample. This feature of LICs may make them particularly difficult to eradicate using therapies targeted against surface antigens.

1 December 2010 in Cancer Cell
Verified
Journal Article
Closed access
JYJenny Yeung
Jenny Yeung
MEMaria Teresa Esposito
Maria Teresa Esposito
AGArnaud Gandillet
Arnaud Gandillet
BZBernd B. Zeisig
Bernd B. Zeisig
EGEmmanuel Griessinger
Emmanuel Griessinger
CSChi Wai Eric So
Chi Wai Eric So

8 December 2014 in Leukemia
Verified
Journal Article
Closed access
CRC Rosilio
C Rosilio
MNM Nebout
M Nebout
VIVeronique Imbert
Veronique Imbert
EGE Griessinger
E Griessinger
ZNZ Neffati
Z Neffati
JPJean-François Peyron
Jean-François Peyron

30 July 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
FMFarideh Miraki-Moud
Farideh Miraki-Moud
FAFernando Anjos-Afonso
Fernando Anjos-Afonso
KHKatharine A. Hodby
Katharine A. Hodby
EGEmmanuel Griessinger
Emmanuel Griessinger
GRGuglielmo Rosignoli
Guglielmo Rosignoli
DTDavid C. Taussig
David C. Taussig
Acute myeloid leukemia (AML) induces bone marrow (BM) failure in patients, predisposing them to life-threatening infections and bleeding. The mechanism by which AML mediates this complication is unknown but one widely accepted explanation is that AML depletes the BM of hematopoietic stem cells (HSCs) through displacement. We sought to investigate how AML affects hematopoiesis by quantifying residual normal hematopoietic subpopulations in the BM of immunodeficient mice transplanted with human AML cells with a range of genetic lesions. The numbers of normal mouse HSCs were preserved whereas normal progenitors and other downstream hematopoietic cells were reduced following transplantation of primary AMLs, findings consistent with a differentiation block at the HSC–progenitor transition, rather than displacement. Once removed from the leukemic environment, residual normal hematopoietic cells differentiated normally and outcompeted steady-state hematopoietic cells, indicating that this effect is reversible. We confirmed the clinical significance of this by ex vivo analysis of normal hematopoietic subpopulations from BM of 16 patients with AML. This analysis demonstrated that the numbers of normal CD34 + CD38 − stem-progenitor cells were similar in the BM of AML patients and controls, whereas normal CD34 + CD38 + progenitors were reduced. Residual normal CD34 + cells from patients with AML were enriched in long-term culture, initiating cells and repopulating cells compared with controls. In conclusion the data do not support the idea that BM failure in AML is due to HSC depletion. Rather, AML inhibits production of downstream hematopoietic cells by impeding differentiation at the HSC–progenitor transition.